Reality Check on Atypical Antipsychotics
Market access for atypical antipsychotics reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Increasing access restrictions on commercial formularies with the inverse true for medicare formularies
- Class Trends: How prescribers treat atypical antipsychotics different than first generation
- Key Findings: A shift towards more integration of Medicaid benefits into managed care contracts and a slight decline of carve-out financing
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.